- $343.29m
- $201.17m
- 53
- 31
- 75
- 52
R2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Cost of Revenue | |||||
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 12.8 | 24.1 | 37.2 | 37 | 32.1 |
Operating Profit | -12.8 | -24.1 | -37.2 | -37 | -32.1 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -12.7 | -23.7 | -36.8 | -35.2 | -26.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -12.8 | -23.4 | -36.8 | -35.1 | -26.6 |
Net Income Before Extraordinary Items | |||||
Net Income | -12.8 | -23.4 | -36.8 | -35.1 | -26.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -12.8 | -23.4 | -36.8 | -35.1 | -26.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.51 | -1.04 | -0.956 | -0.797 | -0.603 |